a global biotech firm that develops and manufactures biosimilar medicines for patients, will post financial results for the first quarter ended March 31, 2023, after U.S. markets close on Thursday, May 18, 2023.
Alvotech will host an investor conference call on Friday, May 19, 2023, at 8:00 am ET (12:00 pm GMT / 14:00 pm CEST). Investors, media, and the public can listen to the conference call online.
Alvotech’s investor website https://investors.alvotech.com/news-events-presentations has information on how to access the webcast or conference call. Alvotech’s News and Events – Events and Presentations page will archive the webcast for 90 days following the event.
About Alvotech
Alvotech, founded by Robert Wessman, develops and manufactures biosimilar medicines for patients worldwide. Alvotech aims to be a global biosimilar leader by providing high-quality, cost-effective products and services using a fully integrated strategy and broad in-house capabilities. Alvotech has eight biosimilar candidates for autoimmune illnesses, visual problems, osteoporosis, lung disease, and cancer.
Alvotech leverages local expertise and worldwide reach through strategic business alliances in the US, Europe, Japan, China, and other Asian countries, as well as major areas of South America, Africa, and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd.
STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd. (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia, and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia.
Each business alliance covers specific products and geographies. Alvotech is not responsible for its partners’ periodic filings, disclosures, and other reports. Visit www.alvotech.com for details. This press release does not include Alvotech website content.